• Je něco špatně v tomto záznamu ?

Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo

C. Ergen, PM. Niemietz, F. Heymann, M. Baues, F. Gremse, R. Pola, L. van Bloois, G. Storm, F. Kiessling, C. Trautwein, T. Luedde, T. Lammers, F. Tacke,

. 2019 ; 206 (-) : 49-60. [pub] 20190322

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025824

Myeloid immune cells promote inflammation and fibrosis in chronic liver diseases. Drug delivery systems, such as polymers, liposomes and microbubbles, efficiently target myeloid cells in healthy liver, but their targeting properties in hepatic fibrosis remain elusive. We therefore studied the biodistribution of three intravenously injected carrier material, i.e. 10 nm poly(N-(2-hydroxypropyl)methacrylamide) polymers, 100 nm PEGylated liposomes and 2000 nm poly(butyl cyanoacrylate) microbubbles, in two fibrosis models in immunocompetent mice. While whole-body imaging confirmed preferential hepatic uptake even after induction of liver fibrosis, flow cytometry and immunofluorescence analysis revealed markedly decreased carrier uptake by liver macrophage subsets in fibrosis, particularly for microbubbles and polymers. Importantly, carrier uptake co-localized with immune infiltrates in fibrotic livers, corroborating the intrinsic ability of the carriers to target myeloid cells in areas of inflammation. Of the tested carrier systems liposomes had the highest uptake efficiency among hepatic myeloid cells, but the lowest specificity for cellular subsets. Hepatic fibrosis affected carrier uptake in liver and partially in spleen, but not in other tissues (blood, bone marrow, lung, kidney). In conclusion, while drug carrier systems target distinct myeloid cell populations in diseased and healthy livers, hepatic fibrosis profoundly affects their targeting efficiency, supporting the need to adapt nanomedicine-based approaches in chronic liver disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025824
003      
CZ-PrNML
005      
20201222160410.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biomaterials.2019.03.025 $2 doi
035    __
$a (PubMed)30925288
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Ergen, Can $u Department of Medicine I, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Medicine III, University Hospital Aachen, Aachen, Germany.
245    10
$a Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo / $c C. Ergen, PM. Niemietz, F. Heymann, M. Baues, F. Gremse, R. Pola, L. van Bloois, G. Storm, F. Kiessling, C. Trautwein, T. Luedde, T. Lammers, F. Tacke,
520    9_
$a Myeloid immune cells promote inflammation and fibrosis in chronic liver diseases. Drug delivery systems, such as polymers, liposomes and microbubbles, efficiently target myeloid cells in healthy liver, but their targeting properties in hepatic fibrosis remain elusive. We therefore studied the biodistribution of three intravenously injected carrier material, i.e. 10 nm poly(N-(2-hydroxypropyl)methacrylamide) polymers, 100 nm PEGylated liposomes and 2000 nm poly(butyl cyanoacrylate) microbubbles, in two fibrosis models in immunocompetent mice. While whole-body imaging confirmed preferential hepatic uptake even after induction of liver fibrosis, flow cytometry and immunofluorescence analysis revealed markedly decreased carrier uptake by liver macrophage subsets in fibrosis, particularly for microbubbles and polymers. Importantly, carrier uptake co-localized with immune infiltrates in fibrotic livers, corroborating the intrinsic ability of the carriers to target myeloid cells in areas of inflammation. Of the tested carrier systems liposomes had the highest uptake efficiency among hepatic myeloid cells, but the lowest specificity for cellular subsets. Hepatic fibrosis affected carrier uptake in liver and partially in spleen, but not in other tissues (blood, bone marrow, lung, kidney). In conclusion, while drug carrier systems target distinct myeloid cell populations in diseased and healthy livers, hepatic fibrosis profoundly affects their targeting efficiency, supporting the need to adapt nanomedicine-based approaches in chronic liver disease.
650    _2
$a zvířata $7 D000818
650    _2
$a lékové transportní systémy $7 D016503
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a imunohistochemie $7 D007150
650    _2
$a liposomy $x chemie $7 D008081
650    _2
$a jaterní cirhóza $x metabolismus $7 D008103
650    _2
$a lymfocyty $x metabolismus $7 D008214
650    _2
$a makrofágy $x metabolismus $7 D008264
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a mikrobubliny $7 D045423
650    _2
$a fluorescenční mikroskopie $7 D008856
650    _2
$a nanomedicína $7 D050997
650    _2
$a polymery $x chemie $7 D011108
650    _2
$a rentgenová mikrotomografie $7 D055114
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Niemietz, Patricia Maria $u Department of Medicine III, University Hospital Aachen, Aachen, Germany.
700    1_
$a Heymann, Felix $u Department of Medicine III, University Hospital Aachen, Aachen, Germany; Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany.
700    1_
$a Baues, Maike $u Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.
700    1_
$a Gremse, Felix $u Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.
700    1_
$a Pola, Robert $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a van Bloois, Louis $u Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
700    1_
$a Storm, Gert $u Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
700    1_
$a Kiessling, Fabian $u Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.
700    1_
$a Trautwein, Christian $u Department of Medicine III, University Hospital Aachen, Aachen, Germany.
700    1_
$a Luedde, Tom $u Department of Medicine III, University Hospital Aachen, Aachen, Germany.
700    1_
$a Lammers, Twan $u Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.
700    1_
$a Tacke, Frank $u Department of Medicine III, University Hospital Aachen, Aachen, Germany; Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany. Electronic address: frank.tacke@gmx.net.
773    0_
$w MED00000753 $t Biomaterials $x 1878-5905 $g Roč. 206, č. - (2019), s. 49-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30925288 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160406 $b ABA008
999    __
$a ok $b bmc $g 1599969 $s 1116510
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 206 $c - $d 49-60 $e 20190322 $i 1878-5905 $m Biomaterials $n Biomaterials $x MED00000753
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace